{"nctId":"NCT00425308","briefTitle":"Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.","startDateStruct":{"date":"2006-10"},"conditions":["Renal Transplantation"],"count":30,"armGroups":[{"label":"Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)","Drug: Steroids"]},{"label":"Everolimus + Cyclosporine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Everolimus + Cyclosporine","Drug: Steroids"]}],"interventions":[{"name":"Everolimus + Cyclosporine","otherNames":["Cyclosporine Microemulsion","Neoral"]},{"name":"Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)","otherNames":["Myfortic"]},{"name":"Steroids","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Patients who participated in and completed study CRAD001A2420\n\nExclusion criteria:\n\n* Premature study or study treatment discontinuation in CRAD001A2420 study.\n* Acute rejection within the 3 months prior to inclusion\n\nOther protocol-defined inclusion/exclusion criteria may apply","sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glomerular Filtration Rate Estimated by Iohexol Plasma Clearance 12 Months After Randomization Between the 2 Groups of Patients.","description":"Primary efficacy endpoint: between treatment analysis of change in iohexol plasmatic clearance (mL/min) from baseline to Month 12 (M12)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.07","spread":"5.03"},{"groupId":"OG001","value":"10.30","spread":"4.84"}]}]}]},{"type":"PRIMARY","title":"Change in the Glomerular Filtration Rate Estimated by Iohexol Plasma Clearance 12 Months After Randomization Between the 2 Groups of Patients Who Completed Trial","description":"Primary efficacy endpoint: between treatment analysis of change in iohexol plasmatic clearance (mL/min) from baseline to Month 12 (M12)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":"6.60"},{"groupId":"OG001","value":"12.00","spread":"5.06"}]}]}]},{"type":"SECONDARY","title":"Change in Renal Function Assessed by Serum Creatinine at Month 3, Month 6 and Month 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161.7","spread":"60.78"},{"groupId":"OG001","value":"153.2","spread":"47.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156.6","spread":"51.41"},{"groupId":"OG001","value":"138.9","spread":"40.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"170.8","spread":"59.36"},{"groupId":"OG001","value":"139.8","spread":"42.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"227.7","spread":"144.0"},{"groupId":"OG001","value":"130.4","spread":"40.27"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Biopsy-proven Acute Rejection (BPAR) at Month 6 and Month 12.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Failures Assessed by Biopsy-proven Acute Rejection (BPAR), Graft Loss/Re-transplantation, Death or Lost to Follow-up at Month 12.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Renal Function Assessed by Creatinine Clearance at Month 3, Month 6 and Month 12","description":"Change in creatinine clearance, Nankivell formula (mL/min/1.73mÂ²) from baseline to M12","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":"20.07"},{"groupId":"OG001","value":"60.3","spread":"18.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":"19.49"},{"groupId":"OG001","value":"67.1","spread":"19.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.3","spread":"15.98"},{"groupId":"OG001","value":"68.1","spread":"18.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.7","spread":"24.70"},{"groupId":"OG001","value":"70.1","spread":"18.34"}]}]}]},{"type":"SECONDARY","title":"Change in Renal Function Assessed by Proteinuria at Month 3, Month 6 and Month 12","description":"Change in proteinuria (g/24h) from baseline to M12","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.447"},{"groupId":"OG001","value":"0.47","spread":"0.390"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"0.248"},{"groupId":"OG001","value":"0.24","spread":"0.267"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.335"},{"groupId":"OG001","value":"0.33","spread":"0.262"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"0.537"},{"groupId":"OG001","value":"0.75","spread":"0.732"}]}]}]},{"type":"SECONDARY","title":"Assessing Cardiovascular Risk Factors Based on Fasting Glucose.","description":"Blood chemistry - fasting glycemia (mmol/L)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"0.97"},{"groupId":"OG001","value":"5.2","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"0.90"},{"groupId":"OG001","value":"5.3","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"1.26"},{"groupId":"OG001","value":"5.2","spread":"1.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"1.15"},{"groupId":"OG001","value":"5.1","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"1.04"},{"groupId":"OG001","value":"5.6","spread":"1.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"0.94"},{"groupId":"OG001","value":"5.4","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Assessing Cardiovascular Risk Factors Based on Fasting Total Cholesterol.","description":"Blood chemistry - total cholesterol (mmol/L)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"1.42"},{"groupId":"OG001","value":"6.0","spread":"2.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"1.20"},{"groupId":"OG001","value":"5.7","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"1.77"},{"groupId":"OG001","value":"5.6","spread":"1.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"1.60"},{"groupId":"OG001","value":"5.7","spread":"1.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"1.49"},{"groupId":"OG001","value":"5.4","spread":"1.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"1.61"},{"groupId":"OG001","value":"5.8","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Assessing Cardiovascular Risk Factors Based on Fasting High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol.","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.89"},{"groupId":"OG001","value":"3.1","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"0.54"},{"groupId":"OG001","value":"1.5","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"0.89"},{"groupId":"OG001","value":"3.4","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.75"},{"groupId":"OG001","value":"1.5","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.15"},{"groupId":"OG001","value":"3.3","spread":"1.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"0.47"},{"groupId":"OG001","value":"1.4","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"0.84"},{"groupId":"OG001","value":"3.2","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.74"},{"groupId":"OG001","value":"1.5","spread":"0.52"}]}]}]},{"type":"SECONDARY","title":"Assessing Cardiovascular Risk Factors Based on Fasting Triglycerides.","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.43"},{"groupId":"OG001","value":"1.8","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.16"},{"groupId":"OG001","value":"2.0","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"0.78"},{"groupId":"OG001","value":"2.2","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"0.51"},{"groupId":"OG001","value":"2.1","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"0.77"},{"groupId":"OG001","value":"2.2","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.05"},{"groupId":"OG001","value":"2.3","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Assessing Cardiovascular Risk Factors Based on Fasting C-reactive Protein (CRP).","description":"Blood chemistry - C-reactive Protein (CRP) (mg/L)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":"17.83"},{"groupId":"OG001","value":"3.0","spread":"2.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"4.88"},{"groupId":"OG001","value":"10.3","spread":"16.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"8.24"},{"groupId":"OG001","value":"5.6","spread":"5.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.2","spread":"62.92"},{"groupId":"OG001","value":"12.6","spread":"27.23"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":15},"commonTop":["Oedema peripheral","Anaemia","Aphthous stomatitis","Dyslipidaemia","Diarrhoea"]}}}